teva-english-logo-gray
1 August 2013Europe

UK Appeals Court upholds Teva’s Copaxone patent

The Court of Appeal for England and Wales has upheld the Patent Court’s decision that Teva Pharmaceutical Industries’ UK patent 762,888, relating to the multiple sclerosis drug Copaxone, is valid.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
26 November 2013   Drugmakers Teva and Mylan Inc have agreed to settle and dismiss pending patent litigation involving Teva's branded Copaxone product in the UK, France and the Netherlands.

More on this story

Big Pharma
26 November 2013   Drugmakers Teva and Mylan Inc have agreed to settle and dismiss pending patent litigation involving Teva's branded Copaxone product in the UK, France and the Netherlands.

More on this story

Big Pharma
26 November 2013   Drugmakers Teva and Mylan Inc have agreed to settle and dismiss pending patent litigation involving Teva's branded Copaxone product in the UK, France and the Netherlands.